ATE370948T1 - Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen - Google Patents

Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen

Info

Publication number
ATE370948T1
ATE370948T1 AT03731906T AT03731906T ATE370948T1 AT E370948 T1 ATE370948 T1 AT E370948T1 AT 03731906 T AT03731906 T AT 03731906T AT 03731906 T AT03731906 T AT 03731906T AT E370948 T1 ATE370948 T1 AT E370948T1
Authority
AT
Austria
Prior art keywords
sup
inhibitors
hiv
compounds
aids
Prior art date
Application number
AT03731906T
Other languages
English (en)
Inventor
Melissa Egbertson
Jeffrey Melamed
H Marie Langford
Steven Young
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE370948T1 publication Critical patent/ATE370948T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
AT03731906T 2002-01-17 2003-01-13 Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen ATE370948T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34977502P 2002-01-17 2002-01-17

Publications (1)

Publication Number Publication Date
ATE370948T1 true ATE370948T1 (de) 2007-09-15

Family

ID=27613314

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03731906T ATE370948T1 (de) 2002-01-17 2003-01-13 Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen

Country Status (9)

Country Link
US (1) US7279487B2 (de)
EP (1) EP1467970B1 (de)
JP (1) JP4523281B2 (de)
AT (1) ATE370948T1 (de)
AU (1) AU2003216049B2 (de)
CA (1) CA2472372C (de)
DE (1) DE60315796T2 (de)
ES (1) ES2291642T3 (de)
WO (1) WO2003062204A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667307B2 (en) * 1997-12-19 2003-12-23 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US7169932B2 (en) 2001-06-11 2007-01-30 Pfizer Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis
US7094909B2 (en) 2001-06-11 2006-08-22 Agouron Pharmaceuticals, Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
HN2002000136A (es) 2001-06-11 2003-07-31 Basf Ag Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
DE60322920D1 (de) 2002-08-13 2008-09-25 Shionogi & Co Heterocyclische verbindungen mit hiv-integrase-hemmender wirkung
PA8586801A1 (es) 2002-10-31 2005-02-04 Pfizer Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
MXPA05007010A (es) * 2002-12-27 2005-08-18 Angeletti P Ist Richerche Bio Tetrahidro-4h-pirido[1,2-a]pirimidinas y compuestos relacionados utiles como inhibidores de la integrasa del virus de inmunodeficiencia humana.
CA2513141A1 (en) 2003-01-27 2004-08-12 Pfizer Inc. Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
AU2004285449A1 (en) 2003-10-20 2005-05-12 Merck & Co., Inc. Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors
KR20070002006A (ko) 2004-02-11 2007-01-04 스미스클라인 비참 코포레이션 Ｈｉｖ 인테그라제 억제제
JP2007528394A (ja) 2004-03-09 2007-10-11 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬
CN101014574A (zh) 2004-03-09 2007-08-08 默克公司 Hiv整合酶抑制剂
WO2005087766A1 (en) 2004-03-09 2005-09-22 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv integrase inhibitors
EP1725556A1 (de) * 2004-03-09 2006-11-29 Merck & Co., Inc. Hiv-integrasehemmer
MXPA06012449A (es) 2004-04-26 2007-01-17 Pfizer Inhibidores de la enzima integrasa de vih.
DE602005002746T2 (de) 2004-04-26 2008-02-07 Pfizer Inc. Inhibitoren des hiv-integrase-enzyms
JP4824673B2 (ja) * 2004-05-07 2011-11-30 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｉｖインテグラーゼ阻害剤
CA2568389A1 (en) 2004-06-09 2005-12-22 Merck & Co., Inc. Hiv integrase inhibitors
JP5116660B2 (ja) * 2005-03-31 2013-01-09 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Ｈｉｖインテグラーゼ阻害剤
DK1874117T3 (da) 2005-04-28 2013-09-23 Viiv Healthcare Co Polycyklisk carbamoylpyridonderivat med hiv-integrasehæmmende aktivitet
WO2006121831A2 (en) * 2005-05-10 2006-11-16 Merck & Co., Inc. Hiv integrase inhibitors
WO2007019100A2 (en) * 2005-08-04 2007-02-15 Smithkline Beecham Corporation Hiv integrase inhibitors
US20080234231A1 (en) * 2005-08-04 2008-09-25 Johns Brian A Hiv Integrase Inhibitors
EP1910356A4 (de) * 2005-08-04 2009-10-21 Smithkline Beecham Corp Hiv-integrasehemmer
US7939537B2 (en) 2005-10-04 2011-05-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HIV integrase inhibitors
JP2009513640A (ja) * 2005-10-27 2009-04-02 メルク エンド カムパニー インコーポレーテッド Ｈｉｖインテグラーゼインヒビター
WO2008004100A2 (en) 2006-07-05 2008-01-10 Pfizer Products Inc. Therapeutic compounds
PT2049506E (pt) 2006-07-07 2015-10-09 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
WO2008010964A1 (en) * 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
US20100216834A1 (en) * 2006-10-18 2010-08-26 Isaacs Richard C A Hiv integrase inhibitors
BRPI0807581A2 (pt) * 2007-02-23 2014-07-01 Gilead Science, Inc. Moduladores de propriedades farmacocinéticas de produtos terapêuticos
EP3023426A1 (de) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazonhemmerverbindungen und krebsbehandlungsverfahren
WO2010011818A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
MX2011003637A (es) * 2008-10-06 2011-04-27 Merck Sharp & Dohme Inhibidores de la integrasa del virus de inmunodeficiencia humana.
SG181423A1 (en) 2009-12-23 2012-07-30 Univ Leuven Kath Novel antiviral compounds
US8283366B2 (en) 2010-01-22 2012-10-09 Ambrilia Biopharma, Inc. Derivatives of pyridoxine for inhibiting HIV integrase
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US8962598B2 (en) 2010-10-14 2015-02-24 Immunahr Ab 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as AHR activators
NZ610315A (en) 2010-11-15 2015-08-28 Univ Leuven Kath Antiviral condensed heterocyclic compounds
CA2817896A1 (en) 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibitors of hiv replication
WO2014099586A1 (en) 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
WO2014172188A2 (en) 2013-04-16 2014-10-23 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
HUE036384T2 (hu) 2013-05-17 2018-07-30 Merck Sharp & Dohme Fúzionált triciklusos heterociklikus vegyületek mint HIV integráz inhibitorok
EP3008044B1 (de) 2013-06-13 2018-11-21 Merck Sharp & Dohme Corp. Kondensierte tricyclische heterocyclische verbindungen als hiv-integrase-hemmer
AU2014324829B2 (en) 2013-09-27 2017-09-07 Merck Sharp & Dohme Corp. Substituted Quinolizine Derivatives useful as HIV integrase inhibitors
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
EP3377066B1 (de) 2015-11-17 2021-04-07 Merck Sharp & Dohme Corp. Amidosubstituierte pyridotriazinderivate als hiv-integrase-hemmer
US10544155B2 (en) 2015-12-15 2020-01-28 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
CN106008283B (zh) * 2016-06-29 2018-03-16 常州市阳光药业有限公司 牛磺酰胺盐酸盐的制备方法
MX384729B (es) 2016-12-02 2025-03-14 Merck Sharp & Dohme Compuestos heterocíclicos tricíclicos útiles como inhibidores de la integrasa del virus de inmunodeficiencia humana (vih).
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
WO2018140368A1 (en) 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
CA3181538A1 (en) * 2020-05-05 2021-11-11 Teon Therapeutics, Inc. Cannabinoid receptor type 2 (cb2) modulators and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5268193A (en) * 1975-11-28 1977-06-06 Sumitomo Chem Co Ltd Synthesis of novel cephalosporin derivatives
FR2632639B1 (fr) 1988-06-09 1990-10-05 Sanofi Sa Derives d'amino-4 carboxy-3 naphtyridines, leur preparation et compositions pharmaceutiques qui les contiennent
SE9000624D0 (sv) * 1990-02-22 1990-02-22 Pharmacia Ab New use
CA2091173A1 (en) * 1990-09-07 1992-03-08 Adriano Afonso Antiviral compounds and antihypertensive compounds
IL101860A0 (en) 1991-05-31 1992-12-30 Ici Plc Heterocyclic derivatives
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5519021A (en) 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
DE4303657A1 (de) * 1993-02-09 1994-08-11 Bayer Ag Neue Chinolon- und Naphthyridoncarbonsäurederivate
GB9312891D0 (en) 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
GB9420172D0 (en) 1994-10-06 1994-11-23 Boots Co Plc Therapeutic agents
GB9420168D0 (en) 1994-10-06 1994-11-23 Boots Co Plc Therapeutic agents
US5801183A (en) 1995-01-27 1998-09-01 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
US5945431A (en) * 1996-03-15 1999-08-31 Biochem Therapeutics Incorporated Cytomegalovirus inhibiting compounds
AU4172197A (en) * 1996-09-10 1998-04-02 Pharmacia & Upjohn Company 8-hydroxy-7-substituted quinolines as anti-viral agents
EP1007526A1 (de) 1997-08-25 2000-06-14 Neurogen Corporation Substituierte 4-oxo-naphthyridine-3-carbonsaeureamide als gaba-rezeptorliganden des gehirns
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
WO2002030931A2 (en) 2000-10-12 2002-04-18 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
DE60322920D1 (de) * 2002-08-13 2008-09-25 Shionogi & Co Heterocyclische verbindungen mit hiv-integrase-hemmender wirkung

Also Published As

Publication number Publication date
WO2003062204A1 (en) 2003-07-31
ES2291642T3 (es) 2008-03-01
CA2472372C (en) 2010-08-17
US7279487B2 (en) 2007-10-09
DE60315796D1 (de) 2007-10-04
AU2003216049B2 (en) 2008-07-17
EP1467970A1 (de) 2004-10-20
EP1467970B1 (de) 2007-08-22
JP4523281B2 (ja) 2010-08-11
DE60315796T2 (de) 2008-06-05
JP2005519907A (ja) 2005-07-07
US20050119482A1 (en) 2005-06-02
CA2472372A1 (en) 2003-07-31
EP1467970A4 (de) 2005-12-21

Similar Documents

Publication Publication Date Title
ATE370948T1 (de) Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen
NO2020026I1 (no) Raltegravir eller et farmasøytisk akseptabelt salt derav, spesielt kaliumsaltet
ATE355064T1 (de) Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
ATE364385T1 (de) Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
ATE345129T1 (de) Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
WO2005086700A3 (en) Hiv integrase inhibitors
WO2004024078A3 (en) Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
ATE409187T1 (de) N-(substituierte benzyl)-8-hydroxy-1,6- naphthyridin-7- carbonsäureamide als hiv- integrase-hemmer
WO2005110414A3 (en) Hiv integrase inhibitors
DE60322919D1 (de) 8-hydroxy-1-oxotetrahydropyrrolopyrazinverbindungen, die sich als inhibitoren von hiv-integrase eignen
WO2005120516A3 (en) Hiv integrase inhibitors
TW200640460A (en) HIV integrase inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties